Evaluation of the effectiveness of ALA for an improvement of exercise tolerability in patients with COPD: pilot study

Evaluation of the effectiveness of ALA for an improvement of exercise tolerability in patients with COPD: pilot study - Effectiveness of ALA for an improvement of exercise tolerability in patients with COPD.

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000023179

Enrollment

Registered

2016-07-30

Start date

2016-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic obstructive pulmonary disease

Interventions

5-aminolevulinic acid(ALA)(100mg/day for 4weeks) placebo (4weeks p.o)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1 COPD patients(GOLD II or III) 2 Patients who complain dyspnea on exertion 3 Patients who undergo pulmonary function tests 4 Patients who understand this pilot study 5 Patients who obtained a written informed consent

Exclusion criteria

Exclusion criteria: 1 Patient's will of withdrawal from this study 2 Serious adverse events 3 Worsening of the symptomes due to COPD 4 Chnage of the medications for COPD 5 Doctor's judgement of the discontinuance of the study

Design outcomes

Primary

Measure	Time frame
6-minute walk distance (after 4weeks of ALA or placebo p.o)	—

Countries

Japan

Contacts

Public ContactMitsuaki Sekiya

Juntendo University, Faculty of Medicine Division of Respirology

msekiya@juntendo.ac.jp03-3813-3111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026